Source comparison
CJC-1295 Differs from HGH Therapy: Regulation, Access, and Cost Comparison
Mechanism GHRH receptor agonist. Stimulates endogenous pituitary GH secretion Direct hormone replacement. Bypasses pituitary regulation CJC-1295 preserves feedback loops; rhGH does not Dosing Frequency Weekly (half-life 6–8 days) Daily (half-life 2–4 hours) We
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonist. Stimulates endogenous pituitary GH secretion
- Direct hormone replacement. Bypasses pituitary regulation
- CJC-1295 preserves feedback loops; rhGH does not
- Dosing Frequency
- Weekly (half-life 6–8 days)
- Daily (half-life 2–4 hours)
- Weekly dosing reduces injection burden but creates pulsatile IGF-1 patterns
- FDA Approval
- None. Research peptide only
- Approved for GH deficiency, Turner syndrome, Prader-Willi, others
- rhGH is prescription-only for verified medical conditions
- IGF-1 Elevation Pattern
- Pulsatile. Peaks at day 6–8, declines by day 12–14
- Stable. Sustained elevation with daily dosing
- Stable IGF-1 may produce more consistent anabolic signaling
- Suppression Risk
- Minimal. Endogenous GH secretion continues
- High. Negative feedback suppresses pituitary GH production
- CJC-1295 discontinuation doesn't require recovery time
- Cost (research/off-label)
- $150–300 per month (weekly 2mg dose)
- $800–1500 per month (daily 0.3mg dose)
- Cost difference reflects synthesis complexity and dosing frequency
- CJC-1295 is not FDA-approved for human use and is sold exclusively as a research chemical under the Federal Food, Drug, and Cosmetic Act. Suppliers like Real Peptides provide research-grade CJC-1295 synthesized under cGMP conditions with third-party purity verification via HPLC and mass spectrometry. Critical quality controls that distinguish legitimate peptide sources from unverified vendors. Recombinant HGH, by contrast, requires a valid prescription and is dispensed through licensed pharmacies. Off-label acquisition of rhGH without prescription is a federal offense under the Federal Food, Drug, and Cosmetic Act and the Anabolic Steroid Control Act of 2004, which classified HGH as a controlled substance when used for performance enhancement.